Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects

Inclusion Criteria: * Equal to or greater than 18 years of age * Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 * Adequate organ function: * Serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥60 mL/min. * Bilirubin ≤ the intuitional upper limits of normal * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to be within institutional normal range * Absolute neutrophil count (ANC) ≥1000mm³ * Platelet count ≥100,000mm³ * Has the capability of understanding the informed consent document and has signed the informed consent document * Sexually active participants (male and female) must use medically acceptable methods of contraception during the course of the study. * Women of childbearing potential must have a negative pregnancy test at screening. * Able to understand and comply with the requirements of the protocol Exclusion Criteria: * receiving investigational therapy (other than the investigational therapy under study) * Have received investigational therapy within 30 days prior to first dose of study drug * Patients who are unable to swallow capsules * Patients with prior malignancies, other than squamous or basal cell carcinomas, unless disease free for ≥ 5 years * Have had prior major surgery within 30 days prior to first dose of study drug * The patient has active infection or fever \>38.5C within 3 days prior to first dose of study drug. * Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Unable or unwilling to stop taking vitamins, herbal remedies, or nonprescription medications * Pregnant or breastfeeding * Unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee